A Phase 3 Open-label Extension Study to Assess the Long-term Safety and Efficacy of Intravenous ATB200 Co-administered With Oral AT2221 in Adult Subjects With Late-onset Pompe Disease

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
  • Age: Between 18 years - 99 years
  • Gender: Female
  • Other Inclusion Criteria:
    1. Subjects willing to provide written informed consent
    2. Subjects must have completed Study ATB200-03
    3. Female subjects of childbearing potential and make subjects must agree to use medically accepted methods of contraception during the study and for 90 days after the last dose of study drug

You may not be eligible for this study if the following are true:

    1. Subjects who plane to receive gene therapy or participate in another interventional study for Pompe disease
    2. Subjects with medical condition or any other extenuating circumstance that may in the opinion of the investigator post an undue safety risk to the subject or may compromise his/her ability to comply with or adversely impact protocol requirements.
    3. Subjects who are pregnant or breastfeeding
    4. Subjects, whether male and female, is planning to conceive a child during the study

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.